Patents by Inventor Nathan Fishkin
Nathan Fishkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945807Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: GrantFiled: May 3, 2022Date of Patent: April 2, 2024Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
-
Publication number: 20230338564Abstract: The present disclosure provides neoDegraders and neoDegraders conjugated to binding moieties. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.Type: ApplicationFiled: March 31, 2021Publication date: October 26, 2023Applicant: Orum Therapeutics, Inc.Inventors: Nathan FISHKIN, Peter U. PARK
-
Publication number: 20230211008Abstract: The present disclosure provides conjugates comprising a binding moiety and an immunomodulatory imide compound, e.g., substituted isoindoline compound, wherein the immunomodulatory imide compound is conjugated to a binding moiety via an optional linker. Also provided are compositions comprising the conjugates. The conjugates and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.Type: ApplicationFiled: March 31, 2021Publication date: July 6, 2023Applicant: Orum Therapeutics, Inc.Inventors: Nathan FISHKIN, Peter U. PARK
-
Publication number: 20220380352Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: ApplicationFiled: May 3, 2022Publication date: December 1, 2022Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO
-
Patent number: 11352348Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: GrantFiled: November 30, 2020Date of Patent: June 7, 2022Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
-
Publication number: 20220081486Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.Type: ApplicationFiled: June 4, 2021Publication date: March 17, 2022Applicant: Eisai R&D Management Co., Ltd.Inventors: Ryan Henry, Thiwanka Samarakoon, Nathan Fishkin, Ping Zhu, Ermira Pazolli, James Palacino, Juan C. Almagro
-
Publication number: 20220031859Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a herboxidiene splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. The herboxidiene itself is also claimed. Further claims are directed to its use, and to the use of a neoantigen, generated by the herboxidiene or its ADC, or a vaccine against this neoantigen.Type: ApplicationFiled: December 12, 2019Publication date: February 3, 2022Inventors: Nathan Fishkin, Thiwanka Samarakoon, James Palacino, Kenzo Arai, Yoshihiko Kotake, Shinya Okubo, Norio Murai, Masayuki Miyano
-
Publication number: 20210299269Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: ApplicationFiled: May 31, 2019Publication date: September 30, 2021Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong Xiao
-
Publication number: 20210101888Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: ApplicationFiled: November 30, 2020Publication date: April 8, 2021Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO
-
Patent number: 9624240Abstract: The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: GrantFiled: May 21, 2015Date of Patent: April 18, 2017Assignee: ImmunoGen, Inc.Inventor: Nathan Fishkin
-
Publication number: 20170002393Abstract: Compositions and methods for minimizing antibody disulfide bond reduction are described. In one aspect, a composition is provided for culturing mammalian host cells to express an antibody including an anti-reduction agent that minimizes reduction of a disulfide bond in the antibody or fragment thereof. In some other aspects, methods for minimizing disulfide bond reduction; increasing production of an antibody or fragment thereof with intact native disulfide bonds; increasing a ratio of non-reduced to reduced antibody or fragment thereof; producing a therapeutic antibody or fragment thereof by adding a sufficient amount of an anti-reduction agent to a cell culture media, pre-harvest cell culture fluid, or harvest cell culture fluid are described. In another aspect, minimizing disulfide bond reduction in an antibody or fragment thereof culturing the host cell in a concentration of at least about 20% O2 is described.Type: ApplicationFiled: December 3, 2014Publication date: January 5, 2017Applicant: IMMUNOGEN, INC.Inventors: RAJEEVA SINGH, NATHAN FISHKIN, SETH KITCHENER, DEBORAH MESHULAM
-
Patent number: 9353127Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: GrantFiled: February 15, 2012Date of Patent: May 31, 2016Assignee: ImmunoGen, Inc.Inventors: Nathan Fishkin, Michael Miller, Wei Li, Rajeeva Singh
-
Publication number: 20160031902Abstract: The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: ApplicationFiled: May 21, 2015Publication date: February 4, 2016Applicant: IMMUNOGEN, INC.Inventor: Nathan FISHKIN
-
Patent number: 9156854Abstract: The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: GrantFiled: March 20, 2012Date of Patent: October 13, 2015Assignee: Immunogen, Inc.Inventor: Nathan Fishkin
-
Patent number: 8765740Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: GrantFiled: February 15, 2012Date of Patent: July 1, 2014Assignee: ImmunoGen, Inc.Inventors: Wei Li, Michael Miller, Nathan Fishkin, Ravi V. J. Chari
-
Publication number: 20140023665Abstract: The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: ApplicationFiled: March 20, 2012Publication date: January 23, 2014Applicant: IMMUNOGEN, INC.Inventor: Nathan Fishkin
-
Patent number: 8426402Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: February 4, 2010Date of Patent: April 23, 2013Assignee: ImmunoGen, Inc.Inventors: Wei Li, Nathan Fishkin, Robert Zhao, Michael Miller, Ravi Chari
-
Publication number: 20120244171Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: ApplicationFiled: February 15, 2012Publication date: September 27, 2012Applicant: ImmunoGen, Inc.Inventors: Wei Li, Michael Miller, Nathan Fishkin, Ravi V.J. Chari
-
Publication number: 20120238731Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: ApplicationFiled: February 15, 2012Publication date: September 20, 2012Applicant: ImmunoGen, Inc.Inventors: Nathan Fishkin, Michael Miller, Wei Li, Rajeeva Singh
-
Publication number: 20100203007Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: February 4, 2010Publication date: August 12, 2010Applicant: Immunogen Inc.Inventors: Wei Li, Nathan Fishkin, Robert Zhao, Michael Miller, Ravi Chari